Who is sponsoring NCT05232552?

NCT05232552 is sponsored by Zhejiang Cancer Hospital.

What drugs are being tested in NCT05232552?

Interventions in NCT05232552: Anlotinib hydrochloride, induction chemotherapy, concurrent chemoradiation.

What condition does NCT05232552 study?

NCT05232552 studies Nasopharyngeal Carcinoma.

Is NCT05232552 still recruiting?

NCT05232552 is currently status unknown. Last updated 10 February 2022.

Last reviewed 2022-02-10 · How we verify

NCT05232552

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma

Status unknown Phase 2 Last updated 10 February 2022

What this trial tests

Phase 2 trial testing Anlotinib hydrochloride in Nasopharyngeal Carcinoma in 37 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
31 December 2022

31 December 2024

Quick facts

Lead sponsor	Zhejiang Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	1 January 2021
Primary completion	31 December 2022
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Anlotinib hydrochloride
induction chemotherapy — full drug profile →
concurrent chemoradiation — full drug profile →

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Zhejiang Cancer Hospital

Who can join

Adults 18 to 75, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

anlotinib was added to TP inductive chemotherapy and definitive chemoradiation in nasopharyngeal carcinoma patients with N2-3 disease with necrosis or/and ECM

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
Liu H, Tang L, Li Y, Xie W, et al · · 2024 · cited 85× · PMID 38254110 · DOI 10.1186/s12943-023-01928-2
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer.
Wang Z, Anderson KS. · · 2022 · cited 22× · PMID 36165723 · DOI 10.1097/ppo.0000000000000615
Emerging tyrosine kinase inhibitors for head and neck cancer.
Long Z, Grandis JR, Johnson DE. · · 2022 · cited 10× · PMID 36131561 · DOI 10.1080/14728214.2022.2125954

Verify or expand the search:

Other trials of Anlotinib hydrochloride

Trials testing the same drug.

NCT06476093 — SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer · NA · recruiting
NCT05193188 — A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma · Phase 2 · unknown
NCT05539118 — Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma · Phase 1, PHASE2 · not yet recruiting
NCT05883085 — A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL · Phase 2 · unknown
NCT04952493 — Anlotinib or Penpulimab in Combination With RAI for DTC · Phase 2 · unknown

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other Zhejiang Cancer Hospital trials

Trials by the same sponsor.

NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05232552 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
Last refreshed: 10 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05232552.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing